Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2018’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)

– The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects

– The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P-Pharma SAS

Aevi Genomic Medicine Inc

Amarantus Bioscience Holdings Inc

APeT Holding BV

Arcturus Therapeutics Ltd

BCWorld Pharm Co Ltd

BioHealthonomics Inc

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Curemark LLC

DURECT Corp

Heptares Therapeutics Ltd

Highland Therapeutics Inc

IRLAB Therapeutics AB

KemPharm Inc

leon-nanodrugs GmbH

Merck & Co Inc

NeuroDerm Ltd

Novartis AG

Noven Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

P2D Bioscience

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Shire Plc

SK Biopharmaceuticals Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Taisho Pharmaceutical Holdings Co Ltd

Tris Pharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Attention Deficit Hyperactivity Disorder (ADHD) Overview 7

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Attention Deficit Hyperactivity Disorder (ADHD) Companies Involved in Therapeutics Development 28

4P-Pharma SAS 28

Aevi Genomic Medicine Inc 28

Amarantus Bioscience Holdings Inc 28

APeT Holding BV 29

Arcturus Therapeutics Ltd 29

BCWorld Pharm Co Ltd 30

BioHealthonomics Inc 30

Cingulate Therapeutics LLC 31

Collegium Pharmaceutical Inc 31

Curemark LLC 32

DURECT Corp 32

Heptares Therapeutics Ltd 32

Highland Therapeutics Inc 33

IRLAB Therapeutics AB 33

KemPharm Inc 34

leon-nanodrugs GmbH 34

Merck & Co Inc 35

NeuroDerm Ltd 35

Novartis AG 36

Noven Pharmaceuticals Inc 36

Otsuka Holdings Co Ltd 37

Otsuka Pharmaceutical Co Ltd 37

P2D Bioscience 38

RespireRx Pharmaceuticals Inc 38

Reviva Pharmaceuticals Inc 39

Shire Plc 39

SK Biopharmaceuticals Co Ltd 40

Sunovion Pharmaceuticals Inc 40

Supernus Pharmaceuticals Inc 40

Taisho Pharmaceutical Holdings Co Ltd 41

Tris Pharma Inc 42

Attention Deficit Hyperactivity Disorder (ADHD) Drug Profiles 43

(nicotine + opipramol hydrochloride) Drug Profile 43

4-P003 Drug Profile 45

atomoxetine hydrochloride Drug Profile 46

BCWPE-003 Drug Profile 47

BNC-375 Drug Profile 48

CB-8411 Drug Profile 50

centanafadine SR Drug Profile 51

CM-4612 Drug Profile 54

CX-717 Drug Profile 55

dasotraline hydrochloride Drug Profile 58

dexmethylphenidate hydrochloride Drug Profile 63

dextroamphetamine Drug Profile 65

dextroamphetamine Drug Profile 67

dextroamphetamine IR Drug Profile 68

dextroamphetamine MR Drug Profile 70

eltoprazine Drug Profile 72

fasoracetam Drug Profile 77

guanfacine hydrochloride Drug Profile 80

guanfacine hydrochloride ER Drug Profile 81

histamine dihydrochloride Drug Profile 84

HTL-1071 Drug Profile 85

INV-107 Drug Profile 87

KP-415 ER Drug Profile 88

KP-484 Drug Profile 91

Leon-02 Drug Profile 92

levofacetoperane Drug Profile 93

lisdexamfetamine dimesylate Drug Profile 94

mazindol CR Drug Profile 101

methylphenidate ER Drug Profile 104

methylphenidate hydrochloride MR Drug Profile 105

methylphenidate hydrochloride SR Drug Profile 111

modafinil Drug Profile 113

molindone hydrochloride ER Drug Profile 114

niacinamide CR Drug Profile 117

NLS-4 Drug Profile 118

NLS-8 Drug Profile 119

OPC-64005 Drug Profile 120

P-001 Drug Profile 121

PBF-509 Drug Profile 122

PD-3044 Drug Profile 124

PFR-08001 ER Drug Profile 125

PFR-8026 Drug Profile 126

RP-5063 Drug Profile 127

SERx480 Drug Profile 129

SKL-13865 Drug Profile 130

Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder Drug Profile 131

Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder Drug Profile 132

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders Drug Profile 133

Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD Drug Profile 134

TRN-110 Drug Profile 135

TS-141 Drug Profile 136

viloxazine hydrochloride ER Drug Profile 137

VU-0238429 Drug Profile 139

Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects 140

Attention Deficit Hyperactivity Disorder (ADHD) Discontinued Products 145

Attention Deficit Hyperactivity Disorder (ADHD) Product Development Milestones 146

Featured News & Press Releases 146

Appendix 155

Methodology 155

Coverage 155

Secondary Research 155

Primary Research 155

Expert Panel Validation 155

Contact Us 155

Disclaimer 156

List of Tables

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by 4P-Pharma SAS, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Aevi Genomic Medicine Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by APeT Holding BV, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Arcturus Therapeutics Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by BCWorld Pharm Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by BioHealthonomics Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Cingulate Therapeutics LLC, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Collegium Pharmaceutical Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Curemark LLC, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by DURECT Corp, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Heptares Therapeutics Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Highland Therapeutics Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by IRLAB Therapeutics AB, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by KemPharm Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by leon-nanodrugs GmbH, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Merck & Co Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by NeuroDerm Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Novartis AG, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Noven Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Otsuka Holdings Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Otsuka Pharmaceutical Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by P2D Bioscience, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by RespireRx Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Reviva Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Shire Plc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by SK Biopharmaceuticals Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Sunovion Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Supernus Pharmaceuticals Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Pipeline by Tris Pharma Inc, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects, H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects, H1 2018 (Contd..1), H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects, H1 2018 (Contd..2), H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Dormant Projects, H1 2018 (Contd..3), H1 2018

Attention Deficit Hyperactivity Disorder (ADHD) Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2018 12

Number of Products under Development by Companies, H1 2018 13

Number of Products under Development by Universities/Institutes, H1 2018 17

Number of Products by Top 10 Targets, H1 2018 22

Number of Products by Stage and Top 10 Targets, H1 2018 22

Number of Products by Top 10 Mechanism of Actions, H1 2018 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 25

Number of Products by Routes of Administration, H1 2018 28

Number of Products by Stage and Routes of Administration, H1 2018 28

Number of Products by Molecule Types, H1 2018 30

Number of Products by Stage and Molecule Types, H1 2018 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports